Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients  by San-Juan, R. et al.
Epstein-Barr virus-related post-transplant lymphoproliferative disorder in
solid organ transplant recipients
R. San-Juan1, P. Comoli2, S. Caillard3, B. Moulin3, H. H. Hirsch4,5 and P. Meylan6 on behalf of the ESCMID Study Group of Infection
in Compromised Hosts (ESGICH)
1) Unit of Infectious Diseases, Instituto de Investigacion Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid,
Spain, 2) Pediatric Haematology-Oncology and Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 3) Service de Nephrologie
Transplantation, Ho^pitaux Universitaires de Strasbourg, Strasbourg, France, 4) Transplantation & Clinical Virology, Department of Biomedicine, University of
Basel, 5) Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, and 6) Institut de Microbiologie et Service des Maladies Infectieuses,
Centre Hospitalier Universitaire Vaudois et Ecole de Medecine, Lausanne, Switzerland
Abstract
Epstein-Barr virus (EBV) contributes to the pathogenesis of post-transplant lymphoproliferative disease (PTLD) in more than 70% of cases.
EBV DNAemia surveillance has been reported to assist in the prevention and treatment of PTLD in hematopoietic stem-cell transplantation
(HSCT) recipients. Derived from experience in HSCT and taking into account that PCR-based EBV monitoring techniques are currently
available in most solid organ transplant (SOT) centres, there is a great interest in EBV surveillance and prevention of PTLD in SOT recipients.
In the present document we have tried to address from a practical perspective different important topics regarding the prevention and
management of EBV-related PTLD in SOT. To this end, available information on SOT was analysed and combined with potentially useful data
from HSCT and expert observations. The document is therefore structured according to different speciﬁc questions, each of them
culminating in a consensus opinion of the panel of European experts, grading the answers according to internationally recognized levels of
evidence. The addressed issues were grouped under the following topics. (i) Timing and epidemiological data of PTLD. Prophylaxis guided by
clinical risk factors of early and late PTLD in SOT. (ii) Relationship of EBV DNAemia load monitoring and the development of PTLD in solid
organ transplant recipients. (iii) Monitoring of EBV DNAemia after SOT. Which population should be monitored? What is the optimal timing
of the monitoring? (iv) Management of SOT recipients with persistent and/or increasing EBV DNAemia.
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Hot Topics
 EBV serostatus should be determined for all SOT donors
and recipients because an EBV-seronegative recipient with
an EBV-seropositive donor is the most high-risk situation for
development of PTLD (A-II).
 For EBV-negative recipients, the use of T-cell depleting
agents should be avoided if possible (B-II). Anti-CD25 or no
induction should be preferred (B-III).
 Prophylaxis using intravenous immunoglobulins and (Val)-
Ganciclovir should be considered in EBV-seronegative
recipients of EBV-seropositive donor organs (B-II).
 Chronic or persistent high EBV load SOT carriers are more
frequent in primary infections but are not clearly related to a
higher risk of the development of EBV-positive PTLD. A rise
in EBV load could be more informative regarding the risk of
developing PTLD (C-III).
 Universal monitoring of EBV DNAemia is not recommended
in SOT recipients (C-III).
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 Monitoring of EBV DNAemia should be useful for EBV D+/
R- SOT recipients (AII) and should be considered in EBV-
seropositive recipients of lung and intestinal transplants (B-
III).
 For asymptomatic EBV-seropositive SOT recipients under-
going acute rejection therapy, EBV load monitoring should
be initiated (B-III).
 For SOT patients with signiﬁcantly increasing EBV loads
(usually more than 10-fold or >1 log10 cp/mL), regardless of
the EBV-serostatus, a careful clinical and radiological exam-
ination using computer tomography and/or PET-CT should
be performed to search for lymphadenopathy, mass lesions
and other signs of PTLD (B-III).
 For asymptomatic EBV-seropositive SOT recipients without
clinical or radiological evidence of PTLD, but signiﬁcantly
increasing EBV loads, reducing immunosuppression should
be considered (B-III). A change in immunosuppressive
therapy towards a regimen based on a mammalian target
of rapamycin (mTOR) inhibitor may be beneﬁcial, although
data supporting the rationale for this approach in the
preemptive setting are insufﬁcient (C-III).
 There are currently insufﬁcient data to determine the
efﬁcacy of anti-CD20 antibody as a preemptive agent in SOT
recipients with persistent and/or increasing EBV DNAemia,
although in the case of explosive EBV dynamics, many
experts would consider this as preemptive treatment and
follow the EBV loads (C-III).
Introduction
Post-transplant lymphoproliferative disorders (PTLDs) occur
on average in 1 to 16% of solid organ transplantation (SOT)
recipients. The risk depends on the type of transplanted
organ, being higher for the heart and liver as compared with
the kidney, exposure to lymphocyte-depleting antibody ther-
apies, the presence of some speciﬁc risk factors and Epstein-
Barr virus (EBV) infection and the immunity status of the
donor and recipient, being highest in EBV-seronegative
recipients of EBV-seropositive donor organs [1,2]. Accord-
ingly, PTLD occurs at higher rates in paediatric recipients
compared with adult recipients [3,4]. In kidney transplant
patients, early PTLD occurring within the ﬁrst year post-
transplantation has been reported in 0.46 per 100 person
years [5]. PTLD represents a spectrum of diseases that range
from an indolent (polyclonal) lymphoproliferation, which can
resolve following reduction of immunosuppression, to malig-
nant aggressive lymphoma, which has a high mortality despite
intensive chemotherapy [6].
Epstein-Barr virus contributes to the pathogenesis of PTLD
in more than 70% of cases [7,8]. EBV DNAemia surveillance
has been reported to assist in prevention and treatment of
PTLD in hematopoietic stem-cell transplantation recipients
(HSCT) [9]. Derived from experience in HSCT and taking into
account that PCR-based EBV monitoring techniques are
currently available in most SOT centres (unpublished data
from the European Survey of PTLD in SOT, personal
communication, San Juan et al.), there is a great interest in
EBV surveillance and prevention of PTLD in SOT recipients.
Unfortunately, the ﬁrst recommendation documents [10,11]
are limited in their applicability to clinical practice and based on
only limited evidence.
In the present document we have tried to address from a
more practical perspective different important topics regard-
ing the prevention and management of EBV-related PTLD in
SOT. To this end, available information in SOT was analysed
and combined with potentially useful data from HSCT and
expert observations. The document is therefore structured
according to different speciﬁc questions, each of them
culminating in a consensus opinion of the panel of experts,
grading the answers according to internationally recognized
levels of evidence [12].
Timing and Epidemiological Data of PTLD.
Prophylaxis Guided by Clinical Risk Factors
of Early and Late PTLD in SOT
The incidence of post-transplant lymphoproliferative disorder
varies according to the type of transplanted organ and age of
the recipient at time of transplantation. The incidence of PTLD
is higher after intestinal, lung and heart lung transplantation,
ranging from 2 to 10% [13–15], whereas lower rates are
reported after liver and kidney transplantation, ranging from
0.2 to 2.5% [15–17]. Recent registry data, however, suggest
that liver transplant recipients have a higher risk of PTLD
compared with kidney transplant recipients. Hypothetically,
the presence of lymphoid tissues in the hepatic graft might be a
contributing factor [2]. Reports of the UK Transplant Registry
showed that standardized incidence ratios matched for age,
gender and timing of non-Hodgkin lymphoma compared with
the general population in SOT recipients are 12.5 for kidney
recipients, 13.3 for liver recipients, 19.8 for heart recipients
and 30 for lung recipients [18]. In the French Registry, where
all PTLDs in adult kidney transplant patients were recorded
over a 10-year period (1998–2007), PTLD cumulative inci-
dence was 0.35% patient-years at 1 year, 1.2% patient-years at
5 years and 2.1% patient-years at 10 years post-transplanta-
tion [16]. The incidence of PTLD is higher in paediatric (from 1
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to 13%) than in adult transplant populations due to the
differences in risk factor frequencies in children [17,19].
Risk factors for PTLD were established in Europe using
retrospective analysis of transplant registries: CTS (Collabo-
rative Transplant Study, G. Opelz), including also non-
European transplant centres [17]; the French Registry, includ-
ing PTLD occurring after kidney transplantation in adults [16];
and the Sweden SOT cohort [20]. Results of the analyses of
European registries are close to those from the USA (USRDS,
OPTN/UNOS, SRTR and NAPRTCS) and Australia/New
Zealand (ANZDATA) registries for main risk factors (IS and
EBV infection). Some discrepancies exist between registries for
secondary risk factors that are probably due to differences in
the way data were reported or analysed (incomplete infor-
mation or missing data, delay from transplantation, etc.) or
differences in post-transplant patient management. The levels
of evidence of the different analysed risk factors are summa-
rized in Table 1.
Risk factors for early PTLD
Major risk factors for early PTLD are well established: primary
infection in the SOT recipient and burden of immunosuppres-
sion and EBV DNA load.
Epstein-Barr virus seronegativity and EBV mismatch are the
main risk factors for PTLD. Recipient EBV seronegativity was
associated with a 5- to 12-fold higher risk of PTLD in adult
cohorts [16,21–23], but the rate of EBV-seronegative patients
is low among adult SOT recipients, around 10%. In paediatric
populations, the high incidence of EBV seronegativity confers
an even higher risk of PTLD, with an HR ranging from 12 to 18
in mismatched (D+/R) recipients [21,23].
The immunosuppressive load is difﬁcult to estimate and data
regarding the link between immunosuppression and PTLD are
only indirectly and categorically derived from registry analyses
and observational studies. In fact, the role of each drug per se is
difﬁcult to assess in terms of risk of PTLD development [24],
especially as transplant recipients receive a combination of
drugs for induction, maintenance and sometimes rejection
treatment. Depleting T-cell agents such as OKT3 and
polyclonal anti-thymocyte globulins are associated with PTLD
after SOT in most studies, particularly in European series
[16,17,20,25,26]. Some reports from the USA or Australia/
New Zealand [27,28] did not show an association between
induction therapy and PTLD but induction was less frequently
used in these countries than in European countries [29]. Other
analyses corroborate the results of European series [22,30].
Nevertheless, alemtuzumab, a monoclonal antibody directed
against the CD52 surface marker on many leukocytes,
including B and T cells, has not been clearly associated with
an increased risk of EBV-positive PTLD. Thus, despite a
profound overall immunosuppressive effect, the additional
depletion of B cells may reduce the risk of B-cell proliferative
disease.[31]
The role of maintenance immunosuppression is less clear
and data are partly contradictory. An association between
tacrolimus and PTLD was reported in adults [17,20,29,30],
especially in patients not receiving induction, and in paediatric
populations [19,32]. Mycophenolate (MYC) does not seem to
have an impact on PTLD risk despite its more potent
immunosuppressive action, either in registry data
[16,27,29,33,34] or in two case–control studies [35,36].
Azathioprine (AZA) was associated with PTLD compared
with MYC use in liver transplant recipients, but not heart and
kidney transplant recipients, whereas cyclosporine (CyA) was
associated with less PTLD compared with tacrolimus (TAC)
use in kidney and heart but not in liver transplant recipients
[2]. In a recent prospective study of paediatric kidney
transplant recipients, higher immunosuppressive loads and, in
particular, TAC dosing were associated with EBV detection in
whole blood, whereas this was not observed for MYC [37,38].
As MYC not only impairs T-cell but also B-cell proliferation,
the risk of PTLD related to MYC may differ from the more T-
cell-speciﬁc calcineurin inhibitors. However, most studies have
not been designed to address differences in the PTLD-genic
effects in multivariate analyses. Effects of mTORs are even
more controversial. In vitro and in vivo studies in mice showed
inhibition of the proliferation of lymphoblastoid cells or
lymphoid tumours by mTOR inhibitors whereas clinical data
coming from registries showed an increased risk of PTLD in
patients treated by mTOR inhibitors [31,34,39].
Risk factors for late PTLD
Risk factors for late PTLD are less studied because US
registries generally do not perform analyses over 3 years post-
transplantation. Conversely, the CTS, French and ANZDATA
registries are long-term studies that enable us to obtain
information on long-term follow-up (up to 10 years post-
TABLE 1. Levels of evidence of analysed risk factors for
PTLD
Type of
PTLD
Potential risk
factor for PTLD
Level of
evidence References
Early PTLD EBV recipient seronegativity,
D+/R- serostatus
A-II [16,21–23]
Use of anti-lymphocyte
antibodies
B-II [16,17,20,22,25,26,30]
Maintenance IS with
tacrolimus
C-II [17,19,20,29,30,32]
Maintenance IS with
mycophenolate
D-II [16,27,29,33–36]
Late PTLD Older age (>60 years) C-III [16,22]
Long-term IS C-III [16,22]
IS, immunosuppression.
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transplantation). Older age (>60 years) and long-term immu-
nosuppression are the most recognized risk factors for late
PTLD [16,22]. In terms of maintenance immunosuppression,
AZA treatment was associated with late PTLD in the French
Registry [16] and long-term use of calcineurin inhibitors
increased the risk of PTLD by 3–5 in the report of the
ANZDATA registry [16].
EBV infection prophylaxis
Efﬁcient prophylaxis to prevent primary EBV infection and
replication has not been established using the currently
available antiviral drugs and antibody preparations. However,
registry data and smaller single-centre experiences suggest
that a reduction in EBV-associated complications may be
observed in the context of cytomegalovirus (CMV) prophy-
laxis, when using intravenous immunoglobulins (polyvalent or
anti-CMV) or antiviral drugs. In a retrospective analysis, SOT
recipients receiving anti-CMV immunoglobulins for CMV
prophylaxis were less likely to develop PTLD in the ﬁrst year
post-transplant (during the time of prophylaxis) [40]. How-
ever, these data were not conﬁrmed in a randomized
controlled trial using anti-CMV immunoglobulin prophylaxis
vs. placebo in a small number of 82 paediatric liver transplant
recipients in Pittsburgh [41]. Antiviral treatment with ganci-
clovir for CMV prophylaxis reduced the risk of early PTLD by
83% in kidney transplant recipients [42]. In this series,
ganciclovir or its prodrug valganciclovir may be the preferred
drugs for EBV prophylaxis because of their higher in vitro
antiviral activity [42]. Of note, these antiviral drugs are only
effective against lytic EBV replication and do not affect EBV
latency or episomal EBV genome replication in proliferating B
cells [43]. However, antiviral inhibition of lytic EBV replication
may decrease infection of B cells and thereby prevent growth
of the latently infected cell population, and the risk of
lymphoproliferative progression in immunosuppressed
patients as discussed [37,44,45]. Clearly, the optimal dose
and treatment duration have not been established, due to the
lack of speciﬁcally designed controlled trials. Thus, there is no
validated recommendation for PTLD prophylaxis in EBV-
positive recipients.
Recommendations regarding prophylaxis guided by clinical
risk factors:
 EBV serostatus should be determined for all SOT donors
and recipients as an EBV-seronegative recipient and EBV-
seropositive donor is the most high-risk situation for
development of PTLD (A-II).
 If the EBV serostatus of SOT recipients was found to be
negative more than 3 months before transplantation, EBV
serology should be repeated within 2 weeks of transplan-
tation, whenever possible (A-III).
 When EBV serostatus is unreliable due to passive transfer of
maternal or intravenous antibodies, the higher risk situation
should be assumed (i.e. EBV-seronegative recipient and EBV-
seropositive donor, or EBV-seropositive recipient and EBV-
seronegative donor (A-III)).
 For EBV-seronegative recipients, EBV-seronegative SOT
donor organs should be preferred (B-II).
 For EBV-negative recipients, the use of T-cell depleting
agents should be avoided if possible (B-II). Anti-CD25 or no
induction should be preferred (B-III).
 Prophylaxis using intravenous immunoglobulins and (Val)-
Ganciclovir should be considered in EBV-seronegative
recipients of EBV-seropositive donor organs (B-II)
Relationship of EBV DNAemia Load
Monitoring and the Development of PTLD
in Solid Organ Transplant Recipients
Based on the understanding that na€ıve B lymphocyte infection
results in the differentiation of EBV-infected B cells and the
potential for developing lymphoproliferative disease in patients
with cellular immune defects [46], it was hypothesized that
increasing EBV DNA load in the blood or other samples may
be diagnostic of or precede PTLD disease [47].
However, many questions remain unanswered. First, basic
issues, such as which sample matrix should be tested (blood
cells, whole blood, with or without standardization to a
cellular DNA sequence, or plasma/serum compartment [48])
or the timing of monitoring, have not been determined in
sufﬁciently powered prospective studies [4,49–51]. There
are data to suggest that assaying blood cellular samples
provides more sensitive data, while acellular matrices
(plasma/serum) may provide data that are less sensitive but
more speciﬁc for the diagnosis of PTLD in patients at risk
[52]. In addition, the identiﬁcation of a clinical or diagnostic
threshold remains elusive, and EBV load values spanning a
two-log range have been proposed [49]. The availability of a
WHO International Standard for EBV for Nucleic Acid
Techniques [4] should help solve problems of inter-labora-
tory standardization [53].
In addition, recent observations improving the understand-
ing of EBV infection may explain the poor performance of EBV
viral load assays in diagnosing or predicting the occurrence of
PTLD. First, while even non-immunocompromised EBV-
infected hosts have intermittent detectable low-level EBV
DNA in circulating memory B cells [54], solid organ trans-
plantation is frequently followed by a transient rise in blood
EBV DNA that, in some instances, could be detected in more
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than 70% of cases. Although such high rates of EBV DNAemia
detection after SOT have been challenged [55], other groups
have reported rates of EBV DNA detection in over 50% of
SOT recipients [5,56–58].
Second, a pattern of chronic high EBV load carriers (EBV
DNA level >5000 copies/mL of whole blood sustained for
>6 months) has been described in paediatric liver transplant
recipients, some of whom developed late EBV-negative PTLD
[59]. More recently, the detection of higher persisting EBV
loads in adult kidney transplant recipients [57] and other organ
transplant recipients (Gardiol et al., personal communication)
suggests that the major risk factor for developing chronically
(or persistent) elevated EBV DNA load in the blood is primary
EBV infection (D+/R serostatus pattern), while the relation-
ship of this infection pattern with the development of PTLD
has not been clearly demonstrated [38,57,59]. However, a
transient or even persistently elevated EBV DNA level is
commonly observed in the blood of patients after solid organ
transplantation without an obvious relationship with PTLD,
which remains a rare occurrence.
Typically, primary EBV replication in a seronegative SOT
recipient is associated with higher risk of PTLD. Second,
detection of primary EBV replication may be symptomatic of an
acute viral syndrome, but is not symptomatic in many EBV
seronegative SOT patients [38]. Given the lack of consensus on
a static threshold EBV load for diagnosis or for preemptive
intervention [49], some authors have suggested that the rise in
EBV load may be more informative about the risk of developing
PTLD [44,50]. A careful review of published data and their
analysis has been presented using rising and contracting EBV
loads as the result of different ratios of episomal EBV genomes
replicating in proliferating B cells, and lytic EBV genome
replication in progeny virus production [44]. Despite these
preliminary data on EBV replication dynamics, no rigorous
clinical studies of EBV kinetics have been reported that are
comparable to the ones on CMV load dynamics and CMV
disease [60]. In another attempt to improve the speciﬁcity and
positive predictive value of screening assays for PTLD, inves-
tigators have combined EBV DNA blood load with other
predictors, in particular EBV-speciﬁc T-cell responses, suggest-
ing that high EBV DNAemia values in patients with defective
EBV-speciﬁc T-cell response were highly predictive of PTLD
development [61]. However, implementation of EBV-speciﬁc
immune monitoring is not yet available for routine clinical use,
which would permit their stringent clinical validation.
Recommendations regarding relationship of EBV dynamics
and PTLD:
 There is no consensus regarding which type of blood sample
matrix should be tested for EBV DNAemia (C-III). Blood
cellular samples seem to be more sensitive for EBV DNA
detection, while acellular matrices (plasma/serum) may be
more speciﬁc for a diagnosis of PTLD.
 EBV DNAemia detection is common after SOT and does
not seem to be per se related to the development of PTLD
(C-III).
 Chronic or persistent high EBV load SOT carriers are more
frequent in primary infections but are not clearly related to
higher risk of the development of EBV-positive PTLD. A rise
in EBV load could be more informative about the risk of
developing PTLD (C-III).
Monitoring of EBV DNAemia after SOT.
Which Population Should be Monitored?
What is the Optimal Timing of the
Monitoring?
There is no established consensus regarding the most appro-
priate schedule for EBV monitoring after SOT because of the
lack of prospective controlled trials. Nevertheless, it seems
reasonable to monitor EBV at least among patients at high risk
of PTLD. Then EBV mismatched recipients (D+/R) and
intestinal and lung transplant recipients should be screened for
EBV load by quantitative NAT [52,54,62–65]. There is no
recommendation for EBV monitoring in the remaining EBV-
seropositive recipients but caution must be taken in the case of
increased immunosuppression, for example in the case of
intensive anti-rejection treatment. Although no study strictly
demonstrates a signiﬁcant effect of EBV monitoring on PTLD
prevention we can assume that the generalization of EBV
DNAemia monitoring in SOT transplant centres and the
adjustment of immunosuppression burden could represent an
explanation for the decreased incidence of PTLD during the
last decade [16,66].
Optimal timing of the routine monitoring in high-risk
recipients is not formally deﬁned. Although for EBV no actual
accurate kinetic data exist, Funk et al. [44] estimated a viral
doubling time of c. 1–8 days based on data from four published
studies. Therefore it seems reasonable to assess EBV DNAemia
every 2–4 weeks in the ﬁrst 3 months, monthly until 6 months
post-transplantation and then every 3 months for the rest of
the ﬁrst year, given that EBV primary infection and early PTLD
are more frequent during the ﬁrst year post-transplantation.
For EBV mismatched recipients without evidence of primary
EBV replication during the ﬁrst year, we recommend
continuing EBV load screening every 3–6 months until 2 or
3 years post-transplant [67]. For patients with persistent high
viral load or PTLD, EBV monitoring should be extended in
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order to guide lowering of immunosuppression and PTLD
therapy [58,65,68,69].
Recommendations regarding the monitoring of EBV DNA-
emia:
 Universal monitoring of EBV DNAemia is not recommended
in SOT recipients (C-III).
 Monitoring of EBVDNAemia should be useful for EBVD+/R
SOT recipients (AII) and should be considered in EBV-
seropositive recipients of lung and intestinal transplants (B-III).
 A recommended time schedule of monitoring of EBV
DNAemia could be: every 2–4 weeks in the ﬁrst 3 months,
monthly until 6 months post-transplantation and then every
3 months for the rest of the ﬁrst year (C-III),
 In EBV D+/R recipients without evidence of primary EBV
replication during the ﬁrst year, we recommend continuing
EBV load screening every 3–6 months until 2 or 3 years
post-transplant (C-III).
Management of SOT Recipients with
Persistent and/or Increasing EBV DNAemia
Solidorgan transplant recipientswithpersistentdetectionofEBV
loads in whole blood represent a challenge to clinical interpre-
tation and management due to only limited and heterogeneous
clinical studies. Several observations suggest that there is little
attributable risk for EBV-PTLD if typical risk factors are lacking
(i.e. the recipient is EBV seropositive, T-cell depleting antibodies
have not been used, the viral loads are low, and the patient is
asymptomatic (no fever, no lymphadenopathy or splenomegaly,
no atypical lymphocytes and no LDH abnormalities that suggest
PTLD)). In a recent study of kidney transplant recipients,
persisting EBV loads in the ﬁrst 6 months post-transplant were
associated with poor graft outcome, but it is unclear how much
the direct effects of EBV replication or indirect effects, including
changes in immunosuppression, contributed to this association
[57]. In SOT recipients without risk factors, but persistent EBV
loads in whole blood, frequent EBV load monitoring or reducing
immunosuppression is not indicated.
Conversely, occurrence of any of these risk factors would
call for a judicious escalation of measures, including EBV load
monitoring, reducing immunosuppression, considering adjunct
antiviral treatment, radiological search for PTLD, the use of
rituximab or even alternative measures such as adoptive T-cell
therapy.
PTLD evaluation
A ﬁrst step is to reasonably rule out PTLD. This must be
performed, regardless of the EBV-serostatus, in asymptomatic
SOT patients with signiﬁcantly increasing EBV loads (usually
more than ten-fold or >1 log10 cp/mL) and in patients with
persistent EBV loads developing symptoms and signs compat-
ible with mononucleosis-like disease. Clinical data and some
analytical clues regarding an increase in LDH could aid in the
diagnosis [70] and radiological studies using PET-CT, including
the latest technology such as FDG-PET, could add more
conclusive data [71]. Management of SOT with increasing EBV
clinical/radiological evidence of mass lesions or other data
suggestive of PTLD is out of the scope of the present revision
and will not be addressed.
Reduction of immunosuppression
Strategies to prevent the Epstein-Barr virus in the solid organ
transplant setting are most commonly aimed at promoting
immune surveillance, and involve the use of reduction of
immunosuppression as the sole strategy [66] or in combina-
tion with antiviral agents or immune globulins [72]. Depending
on the timing of onset of infection, reduction of immunosup-
presion is an effective measure to induce development of
speciﬁc immunity in EBV-seronegative patients. Conversely,
data obtained in paediatric kidney recipients with sustained
high viral loads, especially late after allografting, showed little
beneﬁt from reduction of immunosuppression [73]. It should
be underlined, however, that reconstitution of immune
responses carries the risk of transplant rejection. Conse-
quently, treatment of persistent high viral load carriers in the
absence of other symptoms or signs should be reserved for
high-risk patients, such as EBV-seronegative recipients at
transplantation, in order to avoid unnecessarily reducing
immunosuppression in a large proportion of patients. Regard-
ing treatment modality, a progressive step-wise reduction
schedule, maintaining the lower therapeutic ranges of calci-
neurin inhibitors and adjusting immunosuppressive drug dos-
age dependent upon blood level monitoring, may avoid onset
of acute rejection. mTOR signalling pathways are activated in
PTLD tissue, and the in vitro anti-proliferative effects of the
mTOR inhibitor rapamycin on EBV-transformed B-cell lines
have been observed [74,75]. An encouraging response after a
conversion from calcineurin inhibitors to an mTOR inhibitor
was reported, although it is not clear whether the effect was
due to a general reduction in immunosuppressive load or to a
direct effect of the drug [76]. However, recent studies
reported slightly increased incidences of PTLD during main-
tenance therapy with mTOR-inhibitor-based immunosuppres-
sion [77].
Antiviral treatment
Unlike EBV-seronegative SOT paediatric patients, for whom
treatment with valganciclovir has shown some beneﬁt in the
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prevention of PTLD [78,79], there is no evidence that antiviral
inhibition of lytic EBV replication by intravenous ganciclovir or
oral valganciclovir is of beneﬁt in EBV-seropositive SOT
recipients with signiﬁcantly increasing EBV loads. However,
some experts would consider the use of these antivirals as an
adjunct to reducing immunosuppression in order to reduce de
novo infection and recruitment of B cells into lymphoprolifer-
ation. Unlike reducing immunosuppression, a partial response
to antivirals should be observable within 1-2 weeks, and their
use be abandoned if that is not observed.
Preemptive therapy with rituximab
Antibody therapy targets B-cell-speciﬁc antigens present on
the surface of EBV-transformed B lymphoblasts. The most
widely used antibody is rituximab, a murine/human chimeric
monoclonal antibody (mAb) directed to the CD20 antigen.
Rituximab has been used as a treatment for PTLD developing
after HSCT and SOT [70,80,81]. Given its proven efﬁcacy,
anti-CD20 mAb has become a standard element of the
treatment for CD20-positive PTLD, alone or in combination
with chemotherapy. Anti-CD20 mAb efﬁcacy as a PTLD
preemptive agent has been demonstrated in HSCT recipients
[82,83], but no data are available in the SOT setting.
Among the observed adverse events associated with the use
of anti-CD20 mAb, depletion of normal B cells, which may be
long-lasting and worsen the underlying post-transplant immune
deﬁciency, is responsible for the development of severe
infections [84]. In SOT recipients taking immunosuppressants
for life, an EBV DNAemia relapse upon B-cell compartment
recovery is expected, as anti-CD20 mAb does not mediate
recovery of EBV-speciﬁc immunity. An additional concern
when employing anti-CD20 mAb in a preemptive strategy is
that rituximab targets only one antigen, and tumour cell
variants with antigenic loss may be selected.
Adoptive T-cell therapy
Epstein-Barr virus proteins expressed on PTLD tumour cells
are potential targets for virus-speciﬁc T-lymphocytes. Adop-
tive immunotherapy using donor-derived EBV-speciﬁc cyto-
toxic T cells (EBV-CTLs) has been used successfully for the
prevention of PTLD in allogeneic stem cell transplant (HSCT)
recipients, but in the solid organ transplant setting, experi-
ence is limited [85]. Some centres have reported the
feasibility of generating autologous EBV-CTLs from SOT
recipients, which may restore short-term EBV-speciﬁc immu-
nity that prevents progression from EBV infection to PTLD
[86,87]. At present, the time and facilities required for
production conﬁnes the use of EBV-CTL to experimental
protocols carried out by a limited number of specialized
centres. One option that would render this therapeutic
approach more accessible to a larger number of patients
includes overcoming the need for patient-dedicated produc-
tion by building a bank of HLA-typed, third-party donor EBV-
speciﬁc T cells [88]. Importantly, both autologous and third-
party allogeneic approaches have generally not caused
immunological side-effects or signiﬁcant toxicities.
Major drawbacks of preemptive immunotherapy with EBV-
speciﬁc T cells include limited in vivo persistence of transferred
T cells in SOT recipients on long-term immunosuppression,
and an intrinsic limitation related to viral monitoring, which
measures the load of episomal DNA within resting circulating
B cells rather than the origin of PTLD tumours (i.e. the
transformed B lymphoblasts potentially present in secondary
lymphoid organs).
Other immunological therapies
Interferon-a (IFNa), a T-helper type 1-associated cytokine, in
addition to its modulator activity on the host immune
response, was also shown to possess antiviral and antiprolif-
erative activity. Limited data in solid organ transplant recipients
indicate that some patients with PTLD may respond to IFNa in
conjunction with a reduction in immunosuppression [89].
However, marrow suppression was an observed side-effect,
and there are concerns that interferon therapy could precip-
itate rejection. Anti-interleukin 6 therapy has also been
explored in the treatment of early PTLD [90].
Recommendations regarding management of EBV DNAemia:
 For asymptomatic EBV-seropositive SOT recipients under-
going acute rejection therapy, EBV load monitoring should
be initiated (B-III).
 For asymptomatic SOT patients with signiﬁcantly increasing
EBV loads (usually more than 10-fold or >1 log10 cp/mL),
regardless of the EBV serostatus, a careful clinical and
radiological examination using computer tomography should
be performed to search for lymphadenopathy, mass lesions
and other compatible signs of PTLD (B-III).
 No general recommendations about the frequency of EBV
load monitoring can be made (C-III). Some experts recom-
mend monthly monitoring for the next 3 months, and 3-
monthly monitoring for 1 year may be considered reason-
able. The frequency of monitoring should be tailored
according to clinical urgency and virological dynamics and
may be as frequent as twice per week.
 For patients with persistent and/or increasing EBV loads
developing symptoms and signs of organ involvement,
mononucleosis-like disease or PTLD, a careful clinical and
radiological examination using computer tomography should
be performed to search for lymphadenopathy, mass lesions
and other compatible signs of PTLD, regardless of the EBV
serostatus (B-III). In the case of a high index of suspicion,
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PET-CT and MRI of the neurocranium should be considered,
and biopsies obtained when positive (C-III).
 For asymptomatic EBV-seropositive SOT recipients without
clinical or radiological evidence of PTLD, but signiﬁcantly
increasing EBV loads, reducing immunosuppression should
be considered (B-III). We recommend a progressive step-
wise reduction schedule, towards the lower therapeutic
ranges of calcineurin inhibitors and adjusting immunosup-
pressive drug dosage in order to avoid onset of acute
rejection (B-III).
 A change in immunosuppressive therapy towards an mTOR-
inhibitor-based regimen may be beneﬁcial, although data
supporting the rationale for this approach in the preemptive
setting are insufﬁcient (C-III).
 In EBV-seropositive SOT recipients with signiﬁcantly
increasing EBV loads some experts would consider the use
of antivirals as an adjunct to reducing immunosuppression in
order to reduce de novo infection and recruitment of B cells
into lymphoproliferation (C-III).
 There are currently insufﬁcient data to determine the
efﬁcacy of anti-CD20 antibody as a preemptive agent in SOT
recipients with persistent and/or increasing EBV DNAemia,
although in the case of explosive EBV dynamics, many
experts would consider this as preemptive treatment and
follow the EBV loads (C-III).
 Currently, the lack of controlled studies does not allow
efﬁcacy assessment of adoptive immunotherapy using
donor-derived EBV-speciﬁc cytotoxic T cells (EBV-CTLs)
in the preemptive setting of persistent and/or increasing EBV
DNAemia (C-III).
 There is no evidence to support the use of interferon-a or
anti-interleukin 6 in a preemptive setting of persistent and/or
increasing EBV DNAemia (C-III).
Transparency Declaration
The authors of the present manuscript do not have a
commercial or other association that might pose a conﬂict
of interests (e.g., pharmaceutical stock ownership, consultancy,
advisory board membership, relevant patents, or research
funding).
References
1. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney
DW. Lymphoma after solid organ transplantation: risk, response to
therapy, and survival at a transplantation centre. J Clin Oncol 2009; 27:
3354–3362.
2. Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associa-
tions between EBV serostatus and organ transplant type in PTLD risk:
an analysis of the SRTR national registry data in the United States. Am J
Transplant 2012; 12: 976–983.
3. Burns DM, Crawford DH. Epstein-Barr virus-speciﬁc cytotoxic
T-lymphocytes for adoptive immunotherapy of post-transplant
lymphoproliferative disease. Blood Rev 2004; 18: 193–209.
4. Green M, Michaels MG. Epstein-Barr virus infection and post-
transplant lymphoproliferative disorder. Am J Transplant 2013; 13
(suppl 3): 41–54.
5. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lympho-
proliferative disorders occurring after renal transplantation in adults:
report of 230 cases from the French registry. Am J Transplant 2006; 6:
2735–2742.
6. Parker A, Bowles K, Bradley JA et al. Diagnosis of post-transplant
lymphoproliferative disorder in solid organ transplant recipients –
BCSH and BTS guidelines. Br J Haematol 2010; 149: 675–692.
7. Allen U, Hebert D, Moore D, Dror Y, Wasfy S. Epstein-Barr virus-
related post-transplant lymphoproliferative disease in solid organ
transplant recipients, 1988–97: a Canadian multi-centre experience.
Pediatr Transplant 2001; 5: 198–203.
8. Hoshida Y, Li T, Dong Z et al. Lymphoproliferative disorders in renal
transplant patients in Japan. Int J Cancer 2001; 91: 869–875.
9. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV
reactivation and post-transplant lymphoproliferative disorders (PTLD)
after allogeneic stem cell transplantation in high-risk patients. Biol Blood
Marrow Transplant 2011; 17: 591–597.
10. Parker A, Bowles K, Bradley JA et al. Management of post-transplant
lymphoproliferative disorder in adult solid organ transplant recipients –
BCSH and BTS guidelines. Br J Haematol 2010; 149: 693–705.
11. Glotz D, Chapman JR, Dharnidharka VR et al. The Seville expert
workshop for progress in post-transplant lymphoproliferative
disorders. Transplantation 2012; 94: 784–793.
12. Kish MA. Guide to development of practice guidelines. Clin Infect Dis
2001; 32: 851–854.
13. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant
lymphoproliferative disorder in the United States: young Caucasian
males are at highest risk. Am J Transplant 2002; 2: 993–998.
14. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney
and heart transplant recipients. Lancet 1993; 342: 1514–1516.
15. Sampaio MS, Cho YW, Qazi Y, Bunnapradist S, Hutchinson IV, Shah T.
Post-transplant malignancies in solid organ adult recipients: an analysis
of the U.S. National Transplant Database. Transplantation 2012; 94:
990–998.
16. Caillard S, Lamy FX, Quelen C et al. Epidemiology of post-transplant
lymphoproliferative disorders in adult kidney and kidney pancreas
recipients: report of the French registry and analysis of subgroups of
lymphomas. Am J Transplant 2012; 12: 682–693.
17. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a
collaborative transplant study report. Am J Transplant 2004; 4: 222–230.
18. Collett D, Mumford L, Banner NR, Neuberger J, Watson C.
Comparison of the incidence of malignancy in recipients of different
types of organ: a UK registry audit. Am J Transplant 2010; 10: 1889–
1896.
19. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE.
Risk factors for post-transplant lymphoproliferative disorder (PTLD) in
pediatric kidney transplantation: a report of the North American
pediatric renal transplant cooperative study (NAPRTCS). Transplanta-
tion 2001; 71: 1065–1068.
20. Fernberg P, Edgren G, Adami J et al. Time trends in risk and risk
determinants of non-Hodgkin lymphoma in solid organ transplant
recipients. Am J Transplant 2011; 11: 2472–2482.
21. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Impact
of Epstein-Barr virus donor and recipient serostatus on the incidence
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 109–118
116 Clinical Microbiology and Infection, Volume 20 Supplement 7, September 2014 CMI
of post-transplant lymphoproliferative disorder in kidney transplant
recipients. Nephrol Dial Transplant 2012; 27: 2971–2979.
22. van Leeuwen MT, Grulich AE, Webster AC et al. Immunosuppression
and other risk factors for early and late non-Hodgkin lymphoma after
kidney transplantation. Blood 2009; 114: 630–637.
23. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for
early-onset and late-onset post-transplant lymphoproliferative disor-
der in kidney recipients in the United States. Am J Hematol 2011; 86:
206–209.
24. Birkeland SA, Hamilton-Dutoit S. Is post-transplant lymphoprolifera-
tive disorder (PTLD) caused by any speciﬁc immunosuppressive drug
or by the transplantation per se? Transplantation 2003; 76: 984–988.
25. Duvoux C, Pageaux GP, Vanlemmens C et al. Risk factors for
lymphoproliferative disorders after liver transplantation in adults: an
analysis of 480 patients. Transplantation 2002; 74: 1103–1109.
26. Bakker NA, van Imhoff GW, Verschuuren EA et al. HLA antigens and
post renal transplant lymphoproliferative disease: HLA-b matching is
critical. Transplantation 2005; 80: 595–599.
27. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ,
Hanto DW. Association of the type of induction immunosuppression
with post-transplant lymphoproliferative disorder, graft survival, and
patient survival after primary kidney transplantation. Transplantation
2003; 76: 1289–1293.
28. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after
renal transplantation in Australia and New Zealand. Transplantation
2005; 80: 193–197.
29. Bustami RT, Ojo AO, Wolfe RA et al. Immunosuppression and the risk
of post-transplant malignancy among cadaveric ﬁrst kidney transplant
recipients. Am J Transplant 2004; 4: 87–93.
30. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Post-
transplant lymphoproliferative disorders after renal transplantation in
the United States in era of modern immunosuppression. Transplantation
2005; 80: 1233–1243.
31. Kirk AD, Cherikh WS, Ring M et al. Dissociation of depletional
induction and post-transplant lymphoproliferative disease in kidney
recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619–
2625.
32. Younes BS, McDiarmid SV, Martin MG et al. The effect of immuno-
suppression on post-transplant lymphoproliferative disease in pediatric
liver transplant patients. Transplantation 2000; 70: 94–99.
33. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH.
Mycophenolate, tacrolimus and post-transplant lymphoproliferative
disorder: a report of the North American pediatric renal transplant
cooperative study. Pediatr Transplant 2002; 6: 396–399.
34. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
Association of immunosuppressive maintenance regimens with post-
transplant lymphoproliferative disorder in kidney transplant recipients.
Transplantation 2012; 93: 73–81.
35. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-
based observational cohort study of the long-term risk of malignancies
in renal transplant patients treated with mycophenolate mofetil. Am J
Transplant 2005; 5: 2954–2960.
36. Funch DP, Ko HH, Travasso J et al. Post-transplant lymphoproliferative
disorder among renal transplant patients in relation to the use of
mycophenolate mofetil. Transplantation 2005; 80: 1174–1180.
37. Hocker B, Bohm S, Fickenscher H et al. (Val-)Ganciclovir prophylaxis
reduces Epstein-Barr virus primary infection in pediatric renal trans-
plantation. Transpl Int 2012; 25: 723–731.
38. Hocker B, FickenscherH,DelecluseHJ et al. Epidemiology andmorbidity
of Epstein-Barr virus infection in pediatric renal transplant recipients: a
multicenter, prospective study. Clin Infect Dis 2013; 56: 84–92.
39. McDonald RA, Smith JM, Ho M et al. Incidence of PTLD in pediatric
renal transplant recipients receiving basiliximab, calcineurin inhibitor,
sirolimus and steroids. Am J Transplant 2008; 8: 984–989.
40. Opelz G, Daniel V, Naujokat C, Fickenscher H, Dohler B. Effect of
cytomegalovirus prophylaxis with immunoglobulin or with antiviral
drugs on post-transplant non-Hodgkin lymphoma: a multicentre
retrospective analysis. Lancet Oncol 2007; 8: 212–218.
41. Green M, Michaels MG, Katz BZ et al. CMV-IVIG for prevention of
Epstein Barr virus disease and post-transplant lymphoproliferative
disease in pediatric liver transplant recipients. Am J Transplant 2006; 6:
1906–1912.
42. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD.
Ganciclovir and acyclovir reduce the risk of post-transplant lympho-
proliferative disorder in renal transplant recipients. Am J Transplant
2005; 5: 2894–2900.
43. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney
SC. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but
not the thymidine kinase (EBV-TK), is required for ganciclovir and
acyclovir inhibition of lytic viral production. J Virol 2010; 84: 4534–4542.
44. Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients:
implications for disease. Lancet Infect Dis 2007; 7: 460–472.
45. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E,
Kenney SC. Epstein-Barr virus lytic infection contributes to lympho-
proliferative disease in a SCID mouse model. J Virol 2005; 79: 13993–
14003.
46. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus
and the origins of associated lymphomas. N Engl J Med 2004; 350:
1328–1337.
47. Cockﬁeld SM. Identifying the patient at risk for post-transplant
lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70–78.
48. Jabs WJ, Hennig H, Kittel M et al. Normalized quantiﬁcation by real-
time PCR of Epstein-Barr virus load in patients at risk for post-
transplant lymphoproliferative disorders. J Clin Microbiol 2001; 39: 564–
569.
49. Gartner B, Preiksaitis JK. EBV viral load detection in clinical virology.
J Clin Virol 2010; 48: 82–90.
50. Allen UD, Preiksaitis JK. Epstein-Barr virus and post-transplant
lymphoproliferative disorder in solid organ transplantation. Am J Trans-
plant 2013; 13(suppl 4): 107–120.
51. Wagner HJ, Wessel M, Jabs W et al. Patients at risk for development of
post-transplant lymphoproliferative disorder: plasma versus peripheral
blood mononuclear cells as material for quantiﬁcation of Epstein-Barr
viral load by using real-time quantitative polymerase chain reaction.
Transplantation 2001; 72: 1012–1019.
52. Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P.
Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral
blood mononuclear cells of transplanted patients by real-time
polymerase chain reaction. Transplantation 2002; 74: 656–664.
53. Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG.
Interlaboratory comparison of Epstein-Barr virus viral load assays. Am
J Transplant 2009; 9: 269–279.
54. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr
virus load monitoring: its role in the prevention and management of
post-transplant lymphoproliferative disease. Transpl Infect Dis 2001; 3:
79–87.
55. San-Juan R, De Dios B, Navarro D et al. Epstein-Barr virus DNAemia is
an early surrogate marker of the net state of immunosuppresion in
solid organ transplant recipients. Transplantation 2013; 95: 688–693.
56. Holmes MV, Caplin B, Atkinson C et al. Prospective monitoring of
Epstein-Barr virus DNA in adult renal transplant recipients during the
early post-transplant period: role of mycophenolate mofetil. Transplan-
tation 2009; 87: 852–856.
57. Bamoulid J, Courivaud C, Coaquette A et al. Subclinical Epstein-Barr
virus viremia among adult renal transplant recipients: incidence and
consequences. Am J Transplant 2013; 13: 656–662.
58. Bakker NA, Verschuuren EA, Erasmus ME et al. Epstein-Barr virus-
DNA load monitoring late after lung transplantation: a surrogate
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 109–118
CMI San-Juan et al. EBV-related PTLD in SOT 117
marker of the degree of immunosuppression and a safe guide to reduce
immunosuppression. Transplantation 2007; 83: 433–438.
59. Gotoh K, Ito Y, Ohta R et al. Immunologic and virologic analyses in
pediatric liver transplant recipients with chronic high Epstein-Barr virus
loads. J Infect Dis 2010; 202: 461–469.
60. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Grifﬁths
PD. Application of viral-load kinetics to identify patients who develop
cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032–
2036.
61. Smets F, Latinne D, Bazin H et al. Ratio between Epstein-Barr viral load
and anti- Epstein-Barr virus speciﬁc T-cell response as a predictive
marker of post-transplant lymphoproliferative disease. Transplantation
2002; 73: 1603–1610.
62. Schubert S, Renner C, Hammer M et al. Relationship of immunosup-
pression to Epstein-Barr viral load and lymphoproliferative disease in
pediatric heart transplant patients. J Heart Lung Transplant 2008; 27:
100–105.
63. Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC. Clinical
signiﬁcance of peripheral blood Epstein-Barr viral load monitoring using
polymerase chain reaction in renal transplant recipients. Pediatr
Transplant 2008; 12: 778–784.
64. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose,
monitor, and prevent post-transplant lymphoproliferative disorder. Clin
Microbiol Rev 2010; 23: 350–366.
65. Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner
GL. Monitoring infection with Epstein-Barr virus among seromismatch
adult renal transplant recipients. Am J Transplant 2011; 2011: 1600–
6143.
66. Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and
immunosuppression alterations can decrease PTLD incidence in
pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222–
2228.
67. D’Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L.
Sustained Epstein-Barr virus detection in paediatric liver transplanta-
tion. Insights into the occurrence of late PTLD. Liver Transpl 2007; 13:
343–348.
68. Green M. Management of Epstein-Barr virus-induced post-transplant
lymphoproliferative disease in recipients of solid organ transplantation.
Am J Transplant 2001; 1: 103–108.
69. Tsai DE, Douglas L, Andreadis C et al. EBV PCR in the diagnosis and
monitoring of post-transplant lymphoproliferative disorder: results of a
two-arm prospective trial. Am J Transplant 2008; 8: 1016–1024.
70. Evens AM, David KA, Helenowski I et al. Multicenter analysis of 80
solid organ transplantation recipients with post-transplantation lym-
phoproliferative disease: outcomes and prognostic factors in the
modern era. J Clin Oncol 2010; 28: 1038–1046.
71. Bakker NA, Pruim J, de Graaf W, van Son WJ, van der Jagt EJ, van
Imhoff GW. PTLD visualization by FDG-pet: improved detection of
extranodal localizations. Am J Transplant 2006; 6: 1984–1985.
72. McDiarmid SV, Jordan S, Kim GS et al. Prevention and preemptive
therapy of postransplant lymphoproliferative disease in pediatric liver
recipients. Transplantation 1998; 66: 1604–1611.
73. Ginevri F, Di Marco E, Parodi A et al. EBV viral load monitoring and
reduction of immunosuppression do not successfully prevent PTLD
after pediatric kidney transplantation. Am J Transplant 2008; 8(suppl 2):
477.
74. Furukawa S, Wei L, Krams SM, Esquivel CO, Martinez OM. Pi3Kd
inhibition augments the efﬁcacy of rapamycin in suppressing prolifer-
ation of Epstein-Barr virus (EBV)+ B cell lymphomas. Am J Transplant
2013; 13: 2035–2043.
75. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM.
Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell
lymphomas through modulation of cell-cycle protein expression.
Transplantation 2007; 83: 1114–1121.
76. Cullis B, D’Souza R, McCullagh P et al. Sirolimus-induced remission of
post-transplantation lymphoproliferative disorder. Am J Kidney Dis
2006; 47: e67–e72.
77. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
Association of immunosuppressive maintenance regimens with post-
transplant lymphoproliferative disorder in kidney transplant recipients.
Transplantation 2011; 93: 73–81.
78. Hierro L, Diez-Dorado R, Diaz C et al. Efﬁcacy and safety of
valganciclovir in liver-transplanted children infected with Epstein-Barr
virus. Liver Transpl 2008; 14: 1185–1193.
79. Venturi C, Bueno J, Gavalda J et al. Impact of valganciclovir on Epstein-
Barr virus polymerase chain reaction in pediatric liver transplantation:
preliminary report. Transplant Proc 2009; 41: 1038–1040.
80. Choquet S, Leblond V, Herbrecht R et al. Efﬁcacy and safety of
rituximab in B-cell post-transplantation lymphoproliferative disorders:
results of a prospective multicenter phase 2 study. Blood 2006; 107:
3053–3057.
81. Trappe R, Oertel S, Leblond V et al. Sequential treatment with
rituximab followed by chop chemotherapy in adult B-cell post-
transplant lymphoproliferative disorder (PTLD): the prospective
international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13:
196–206.
82. van Esser JW, Niesters HG, van der Holt B et al. Prevention of Epstein-
Barr virus-lymphoproliferative disease by molecular monitoring and
preemptive rituximab in high-risk patients after allogeneic stem cell
transplantation. Blood 2002; 99: 4364–4369.
83. Comoli P, Basso S, Zecca M et al. Preemptive therapy of EBV-related
lymphoproliferative disease after pediatric haploidentical stem cell
transplantation. Am J Transplant 2007; 7: 1648–1655.
84. Choquet S, Oertel S, LeBlond V et al. Rituximab in the management
of post-transplantation lymphoproliferative disorder after solid organ
transplantation: proceed with caution. Ann Hematol 2007; 86: 599–
607.
85. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of
post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9:
510–519.
86. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr
virus (EBV)-speciﬁc cytotoxic T cells for prevention of EBV-related
lymphoproliferative disorder in solid organ transplant recipients with
evidence of active virus replication. Blood 2002; 99: 2592–2598.
87. Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ
transplant recipients with autologous Epstein-Barr virus-speciﬁc cyto-
toxic T lymphocytes (CTLS). Blood 2006; 108: 2942–2949.
88. Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell
therapy for EBV-positive post-transplantation lymphoproliferative
disease: results of a phase 2 multicenter clinical trial. Blood 2007;
110: 1123–1131.
89. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy
VC. Interferon-alpha treatment of post-transplant lymphoproliferative
disorder in recipients of solid organ transplants. Transplantation 1998;
66: 1770–1779.
90. Haddad E, Paczesny S, Leblond V et al. Treatment of b-lymphoprolif-
erative disorder with a monoclonal anti-interleukin-6 antibody in 12
patients: a multicenter phase 1-2 clinical trial. Blood 2001; 97: 1590–
1597.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 109–118
118 Clinical Microbiology and Infection, Volume 20 Supplement 7, September 2014 CMI
